FDA's Decline In Promotion Enforcement Highlighted By Celator Booth Letter

07 Sep 2016

• By Michael Cipriano

FDA's Office of Prescription Drug Promotion issues only its third letter of 2016, although it hopes to cast wide net by targeting high-profile events like ASCO.

FDA's enforcement of promotional material has continued to dwindle in recent years, but while the volume has dropped, the pattern in many ways remains the same: The Office of Prescription Drug Promotion (OPDP) has just cited a display from the American Society for Clinical Oncology (ASCO) Annual Meeting – only the office's third letter of the year.

This time, Celator Pharmaceuticals Inc. was deemed the culprit, with the agency saying a placard for the...